Paclitaxel-Loaded PBCA Nanoparticles for Targeted Drug Delivery in Ovarian Cancer
Authors:
Open Access
- 14 July 2025
- journal article
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Biology
- Vol. 10 (3) , 679-687
Abstract
Overview: Resistance to paclitaxel remains a critical barrier in the effective treatment of ovarian cancer, often resulting in reduced clinical responses and increased recurrence rates. Nanoparticle-mediated drug delivery has emerged as a promising strategy to overcome such resistance by enhancing drug bioavailability and targeting tumor cells more precisely. The present study focuses on the formulation of poly(butyl cyanoacrylate) (PBCA) nanoparticles to facilitate controlled paclitaxel delivery and improve its therapeutic efficacy against drug-resistant ovarian cancer cells. Methods: Paclitaxel-loaded PBCA nanoparticles were synthesized using a mini-emulsion polymerization technique. Physicochemical properties were assessed by measuring hydrodynamic size, polydispersity index (PDI), zeta potential, and in vitro drug release behavior. Morphological evaluation was conducted via Scanning Electron Microscopy (SEM) to confirm particle uniformity and surface characteristics. Cytotoxicity was examined against the A2780CIS ovarian cancer cell line following 48 hours of exposure to the nanoformulation and free paclitaxel. Results: The formulated nanoparticles displayed a spherical morphology with an average diameter of 355 nm, a PDI of 0.29, and a surface charge of –18.4 mV. Drug release profiling demonstrated a sustained and controlled release, with approximately 42% of paclitaxel released over 40 hours under physiological conditions. Cellular viability assays revealed that treatment with paclitaxel-loaded PBCA nanoparticles led to a 68% reduction in cell viability, significantly outperforming free paclitaxel, which showed a 41% decrease under identical conditions (p < 0.01). Conclusion: PBCA nanoparticles exhibited favorable physicochemical characteristics and enhanced anticancer activity in paclitaxel-resistant ovarian cancer cells. These findings support their potential application as a targeted and efficient nanocarrier system for improving the therapeutic index of chemotherapeutic agents in drug-refractory malignancies.Keywords
This publication has 76 references indexed in Scilit:
- Cone-Beam Computed Tomography (CBCT) Assessment of the Inter-Radicular Bone Thickness in the Anterior Maxilla in an Iranian PopulationJournal of Maxillofacial and Oral Surgery, 2025
- Hypericin and resveratrol anti‐tumor impact through E‐cadherin, N‐cadherin, galectin‐3, and BAX/BCL‐ratio; possible cancer immunotherapy succor on Y79 retinoblastoma cellsPrecision Medical Sciences, 2025
- Enhancing schizophrenia diagnosis through deep learning: a resting-state fMRI approachNeural Computing and Applications, 2025
- EEG microstate biomarkers for schizophrenia: a novel approach using deep neural networksCognitive Neurodynamics, 2025
- Enhancing Cisplatin Delivery via Liposomal Nanoparticles for Oral Cancer TreatmentIndian Journal of Clinical Biochemistry, 2024
- Effect of Acoustic Cavitation on Mouse Spermatogonial Stem CellsJournal of Ultrasound in Medicine, 2020
- Nanoparticle: Significance as Smart Material in Therapeutic Strategies in Drug Delivery in Biological Systems2019
- Opsonization, Biodistribution, Cellular Uptake and Apoptosis Study of PEGylated PBCA Nanoparticle as Potential Drug Delivery CarrierPharmaceutical Research, 2011
- Paclitaxel-Loaded Poly(n-butylcyanoacrylate) Nanoparticle Delivery System to Overcome Multidrug Resistance in Ovarian CancerPharmaceutical Research, 2010
- Defective Apoptosis Underlies Chemoresistance in Ovarian Cancer2008